Pfizer, Inc.
24.29-0.21 (-0.86%)
Oct 29, 4:00:02 PM EDT · NYSE · PFE · USD
Key Stats
Market Cap
138.10BP/E (TTM)
12.85Basic EPS (TTM)
1.89Dividend Yield
0.07%Recent Filings
8-K
Pfizer Q2 revenues surge 10%
Pfizer reported Q2 2025 revenues of $14.7 billion, up 10% operationally from last year, fueled by Vyndaqel family growth, surging Comirnaty and Paxlovid sales, yet offset by Ibrance declines and IRA discounts. Adjusted diluted EPS hit $0.78, a 30% jump, thanks to cost cuts in SI&A and R&D. The company reaffirmed $61-64 billion full-year revenue guidance but raised adjusted EPS outlook to $2.90-$3.10, absorbing a $0.20 hit from the 3SBio licensing deal. Cost savings initiatives target $7.2 billion by 2027.
10-Q
Q2 FY2025 results
Pfizer's Q2 revenues climbed 10% year-over-year to $14.7B, fueled by Vyndaqel family growth of 22% and Comirnaty's 96% surge, while Paxlovid rebounded 70% amid shifting COVID dynamics; yet Ibrance dipped 7% on generic pressures and IRA discounts. Gross margins held steady at 25.8%, with operating income swinging to $3.0B from a $103M loss, thanks to lower restructuring costs and equity gains, though net income edged to $2.9B as legal charges rose. Diluted EPS hit $0.51, aligning with 5.7B shares, while YTD figures show flat revenues at $28.4B but EPS up to $1.03 on $1.8B operating cash flow versus a $691M outflow. Cash stood at $1.6B with $11.6B short-term investments, total debt $61.8B including fresh €3.3B Euro notes; free cash flow derived at $571M. Patent challenges loom large for key franchises.
8-K
Pfizer completes €3.3B bond offering
Pfizer's Dutch subsidiary completed a €3.3 billion euro-denominated bond offering on May 19, 2025, issuing senior unsecured notes maturing in 2029 at 2.875%, 2032 at 3.250%, 2037 at 3.875%, and 2045 at 4.250%, fully guaranteed by the parent company. This extends Pfizer's debt maturity profile amid favorable euro market conditions. No use of proceeds disclosed. Bonds lock in rates now.
10-Q
Q1 FY2025 results
Pfizer's Q1 FY2025 revenues fell 8% y/y to $13.7B, driven by a sharp 75% operational drop in Paxlovid to $491M amid lower infections, yet Vyndaqel family surged 33% operationally to $1.5B on strong demand, Comirnaty rose 62% to $565M with better U.S. uptake, and oncology stars like Padcev and Lorbrena grew 25% and 39% respectively. Gross margin improved to 79.3% from 77.3%, while operating income dipped 19% y/y to $2.8B, pressured by $678M in restructuring costs for cost realignment programs targeting $5.7B savings through 2027. Diluted EPS held at $0.52, reconciling to 5.71B shares with no anti-dilution flags. Cash swelled to $17.3B including short-term investments, FCF hit $1.8B (derived), and total debt stood at $62.1B with full revolver availability; the Haleon stake sale fetched $6.3B to fuel capital priorities. Patent challenges loom large for key franchises.
8-K
Pfizer Q1 revenues dip, costs slashed
Pfizer reported Q1 2025 revenues of $13.7 billion, down 8% from last year, hit by a 75% plunge in Paxlovid sales yet buoyed by 33% growth in Vyndaqel family and 62% in Comirnaty. Adjusted diluted EPS rose 12% to $0.92, fueled by cost cuts. The company expanded its realignment program, targeting $5.7 billion in net savings by 2027, including $500 million from R&D simplification to reinvest in the pipeline, while reaffirming full-year guidance of $61-64 billion revenues and $2.80-3.00 EPS. Execution sharpens focus amid volatility.
IPO
Website
Employees
Sector
Industry